Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

The Biden administration is set to announce today that it has brokered a deal to get more doses of the Johnson & Johnson COVID vaccine into conflict zones around the world, a senior White House official tells Axios.

Why it matters: Getting the rest of the world vaccinated will save lives — and reduce the chances of more new variants.

How it works: J&J doses could previously only be used for official government vaccination programs due to liability concerns, a senior White House official said.

  • "The way vaccine manufacturers sell or give doses to countries ... is the recipient government essentially accepts legal liability for the doses. That's just the system we've developed," the official said.
  • But in many humanitarian settings and conflict zones, there's no government entity to administer the doses and accept that liability.
  • The U.S., J&J, and the global COVAX initiative built a "novel legal approach" in which J&J agreed to waive the legal liability it normally requires from a country for donated doses.
  • J&J is essentially saying, "we're going to let an NGO give them to people who are most vulnerable because the situation demands it," the official said. They said they expect it could be a model for donations from other vaccine makers.

As part of the deal, the U.S. government will also donate 1.5 million doses of extra domestic supply of J&J shots to COVAX for flexible use in people in conflict zones or other humanitarian settings, such as for migrants or asylum seekers, or where the need is the greatest.

  • Secretary of State Tony Blinken is expected to announce the deal as part of a virtual meeting with foreign ministers today.
  • He will also announce that the U.S facilitated a deal to make an additional 300,000 doses of J&J available for humanitarian, UN peacekeeping, and other frontline workers around the world.

The big picture: Administration officials declined to specify where doses would be allocated.

  • But a report commissioned earlier this year by the Unit for the Protection of Civilians at the International Committee of the Red Cross pointed to examples of conflict zones that couldn't get vaccines, including Iraq, the Philippines, Nigeria, Yemen, the Central African Republic, Colombia, Greece and Azerbaijan.

What they're saying: "From the beginning of the pandemic, our Company has recognized that no one is safe until everyone is safe and has worked to develop and deliver a vaccine that can protect people everywhere.  This includes ensuring that people in conflict zones or other humanitarian settings can access COVID-19 vaccines, even if they live beyond the reach of traditional, state-run vaccination campaigns," a Johnson & Johnson spokesman said in a statement sent to Axios.

Editor's note: This story has been updated with a statement from Johnson & Johnson. It has also been updated to specify J&J's COVID-19 shots to COVAX would be for flexible use in people in conflict zones or other humanitarian settings, such as for migrants or asylum seekers, or where the need is the greatest.

Go deeper

Dec 4, 2021 - Health

Pfizer could have vaccine data for children under five by end of 2021, CEO says

A health care worker administers a dose of the Pfizer-BioNTech COVID vaccine to a child at a Salvation Army vaccination clinic in Philadelphia on Nov. 12. Photo: Hannah Beier/Bloomberg via Getty Images

Pfizer could have data on COVID-19 vaccine efficacy for children under five by the end of the year, CEO Albert Bourla said on Friday in an interview with NBC News.

Why it matters: Omicron has raised concerns that young children are becoming more vulnerable to the virus. Tshwane, the epicenter of South Africa's Omicron outbreak, has seen a high number of hospital admissions for children under two in the last few weeks, though scientists have not confirmed a link to the variant, Reuters reports.

Movie theaters go out of style

Illustration: Sarah Grillo/Axios

Vaccination rates are going up, people are going out to restaurants again — although the new COVID variant may get in the way — but they still aren't rushing back to the movies.

By the numbers: Some 49% of pre-pandemic moviegoers are no longer hitting theaters, according to a study from the film research company The Quorum, as reported by the New York Times.

3 hours ago - Health

Vaccine mandates lose steam in the U.S. while Europe doubles down

Illustration: Sarah Grillo/Axios

European countries are doubling down on pressure campaigns to get people vaccinated just as Republicans continue to wage war — often successfully — against vaccine mandates in the U.S.

Why it matters: The starkly different approaches create a sharp contrast between the regions' approaches to vaccination, even as the Omicron variant rapidly spreads around the world.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!